MX2016009010A - Anticuerpos anti-gen de activacion de linfocitos (lag-3) para tratar neoplasias hematologicas. - Google Patents
Anticuerpos anti-gen de activacion de linfocitos (lag-3) para tratar neoplasias hematologicas.Info
- Publication number
- MX2016009010A MX2016009010A MX2016009010A MX2016009010A MX2016009010A MX 2016009010 A MX2016009010 A MX 2016009010A MX 2016009010 A MX2016009010 A MX 2016009010A MX 2016009010 A MX2016009010 A MX 2016009010A MX 2016009010 A MX2016009010 A MX 2016009010A
- Authority
- MX
- Mexico
- Prior art keywords
- lag
- antibodies
- hematological malignancies
- treat hematological
- lymphocytic leukemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona métodos para el tratamiento clínico de las neoplasias hematológicas, tales como la leucemia linfocítica crónica recidivante o refractaria o el linfoma utilizando un anticuerpo anti-LAG-3. Las neoplasias particulares incluyen, por ejemplo, la leucemia linfocítica crónica (CLL), el linfoma de Hodgkin (HL), o el linfoma no de Hodgkin (NHL).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461932589P | 2014-01-28 | 2014-01-28 | |
PCT/US2015/012916 WO2015116539A1 (en) | 2014-01-28 | 2015-01-26 | Anti-lag-3 antibodies to treat hematological malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016009010A true MX2016009010A (es) | 2017-01-18 |
Family
ID=52478072
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009010A MX2016009010A (es) | 2014-01-28 | 2015-01-26 | Anticuerpos anti-gen de activacion de linfocitos (lag-3) para tratar neoplasias hematologicas. |
MX2022007800A MX2022007800A (es) | 2014-01-28 | 2016-07-08 | Anticuerpos anti-gen de activacion de linfocitos gen-3 (lag-3) para usarse en el tratamiento de neoplasias hematologicas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007800A MX2022007800A (es) | 2014-01-28 | 2016-07-08 | Anticuerpos anti-gen de activacion de linfocitos gen-3 (lag-3) para usarse en el tratamiento de neoplasias hematologicas. |
Country Status (20)
Country | Link |
---|---|
US (4) | US20160326248A1 (es) |
EP (3) | EP3099716A1 (es) |
JP (3) | JP2017505773A (es) |
KR (2) | KR20220147714A (es) |
CN (1) | CN105992595A (es) |
BR (1) | BR112016017174A2 (es) |
CA (1) | CA2937503A1 (es) |
CY (1) | CY1124977T1 (es) |
DK (1) | DK3556775T3 (es) |
EA (1) | EA201691361A1 (es) |
ES (1) | ES2902369T3 (es) |
HR (1) | HRP20212033T1 (es) |
HU (1) | HUE057817T2 (es) |
LT (1) | LT3556775T (es) |
MX (2) | MX2016009010A (es) |
PL (1) | PL3556775T3 (es) |
PT (1) | PT3556775T (es) |
RS (1) | RS62788B1 (es) |
SI (1) | SI3556775T1 (es) |
WO (1) | WO2015116539A1 (es) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
BR122023024195A2 (pt) | 2013-09-20 | 2023-12-26 | Bristol-Myers Squibb Company | Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
CN113603784A (zh) | 2015-05-29 | 2021-11-05 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
GEP20227419B (en) | 2015-07-30 | 2022-10-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
MY192202A (en) | 2015-10-02 | 2022-08-06 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
BR112018011781A2 (pt) | 2015-12-14 | 2018-12-04 | Macrogenics Inc | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica |
AU2016371639A1 (en) * | 2015-12-16 | 2018-06-28 | Merck Sharp & Dohme Llc | Anti-LAG3 antibodies and antigen-binding fragments |
CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
MX2019003683A (es) | 2016-10-11 | 2019-08-22 | Agenus Inc | Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos. |
WO2018089890A1 (en) * | 2016-11-14 | 2018-05-17 | Millennium Pharmaceuticals, Inc. | Non-adult human dosing of anti-cd30 antibody-drug conjugates |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
MD3551660T2 (ro) | 2016-12-07 | 2024-03-31 | Agenus Inc | Anticorpi anti-CTLA-4 și procedee de utilizare a acestora |
JP7267921B2 (ja) | 2017-01-06 | 2023-05-02 | クレシェンド・バイオロジックス・リミテッド | プログラム細胞死(pd-1)に対するシングルドメイン抗体 |
BR112019017329A2 (pt) | 2017-04-03 | 2020-04-14 | Hoffmann La Roche | imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição |
CN110392698B (zh) | 2017-04-05 | 2022-01-25 | 豪夫迈·罗氏有限公司 | 抗lag3抗体 |
US11285207B2 (en) | 2017-04-05 | 2022-03-29 | Hoffmann-La Roche Inc. | Bispecific antibodies specifically binding to PD1 and LAG3 |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
US11339218B2 (en) | 2017-05-10 | 2022-05-24 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Human monoclonal antibodies against LAG3 and uses thereof |
CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
HUE065242T2 (hu) * | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
JP2020524694A (ja) | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのIL−1β結合性抗体 |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER |
CN118307674A (zh) | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
EP3645037A1 (en) | 2017-06-27 | 2020-05-06 | Novartis AG | Dosage regimens for anti-tim-3 antibodies and uses thereof |
US10844121B2 (en) * | 2017-07-13 | 2020-11-24 | Nanjing Leads Biolabs Co., Ltd | Antibodies binding LAG-3 and uses thereof |
KR20200031659A (ko) * | 2017-07-20 | 2020-03-24 | 노파르티스 아게 | 항-lag-3 항체의 투여 요법 및 그의 용도 |
KR20200042937A (ko) | 2017-08-30 | 2020-04-24 | 페인스 테라퓨틱스 인코포레이티드 | 항-lag-3 항체 및 이의 용도 |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
WO2019129137A1 (zh) * | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
EP3737408A1 (en) | 2018-01-08 | 2020-11-18 | Novartis AG | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
EP3746480A1 (en) | 2018-01-31 | 2020-12-09 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
JP7438180B2 (ja) * | 2018-03-20 | 2024-02-26 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗lag-3抗体ポリペプチド |
US20200407447A1 (en) * | 2018-03-22 | 2020-12-31 | Keires Ag | Antagonistic pd-1, pd-l1 and lag-3 binding proteins |
CA3093034A1 (en) | 2018-03-30 | 2019-10-03 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against lag-3 and uses thereof |
EP3778639A4 (en) | 2018-04-02 | 2021-06-09 | Mab-Venture Biopharm Co., Ltd. | ANTIBODIES BINDING TO LYMPHOCYTAIR ACTIVATION GENE 3 (LAG-3) AND ITS USE |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
JP7398396B2 (ja) | 2018-06-01 | 2023-12-14 | ノバルティス アーゲー | Bcmaに対する結合分子及びその使用 |
FI3820573T3 (fi) | 2018-07-10 | 2023-11-01 | Novartis Ag | 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
SG11202104699TA (en) | 2018-12-21 | 2021-07-29 | Novartis Ag | Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome |
US20220056123A1 (en) | 2018-12-21 | 2022-02-24 | Novartis Ag | Use of il-1beta binding antibodies |
BR112021012066A2 (pt) | 2018-12-21 | 2021-11-03 | Onxeo | Novas moléculas de ácido nucleico conjugadas e seus usos |
WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
US11712433B2 (en) | 2019-03-22 | 2023-08-01 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
EP3994132A1 (en) | 2019-07-03 | 2022-05-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
JP2022553306A (ja) | 2019-10-21 | 2022-12-22 | ノバルティス アーゲー | Tim-3阻害剤およびその使用 |
MX2022004766A (es) | 2019-10-21 | 2022-05-16 | Novartis Ag | Terapias combinadas con venetoclax e inhibidores de tim-3. |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
JP2023509516A (ja) | 2020-01-07 | 2023-03-08 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | がん治療のための改良型ヒトメチルチオアデノシン/アデノシン枯渇酵素変種 |
MX2022008763A (es) | 2020-01-17 | 2022-07-27 | Novartis Ag | Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica. |
AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
CN116234568A (zh) | 2020-07-07 | 2023-06-06 | 生物技术公司 | 用于hpv阳性癌症的治疗性rna |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
CN114621345B (zh) | 2020-12-10 | 2022-11-29 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
BR112023019847A2 (pt) | 2021-03-29 | 2023-11-07 | Juno Therapeutics Inc | Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
CN115873116A (zh) | 2021-09-29 | 2023-03-31 | 中山康方生物医药有限公司 | 抗lag3抗体、药物组合物及用途 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023072294A1 (en) * | 2021-11-01 | 2023-05-04 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-lag3 antibodies |
AU2022409713A1 (en) | 2021-12-16 | 2024-06-20 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
BR122023024195A2 (pt) * | 2013-09-20 | 2023-12-26 | Bristol-Myers Squibb Company | Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1 |
-
2015
- 2015-01-26 CA CA2937503A patent/CA2937503A1/en active Pending
- 2015-01-26 RS RS20211606A patent/RS62788B1/sr unknown
- 2015-01-26 ES ES19161885T patent/ES2902369T3/es active Active
- 2015-01-26 MX MX2016009010A patent/MX2016009010A/es unknown
- 2015-01-26 EA EA201691361A patent/EA201691361A1/ru unknown
- 2015-01-26 LT LTEP19161885.9T patent/LT3556775T/lt unknown
- 2015-01-26 CN CN201580006297.5A patent/CN105992595A/zh active Pending
- 2015-01-26 KR KR1020227036733A patent/KR20220147714A/ko not_active Application Discontinuation
- 2015-01-26 JP JP2016548710A patent/JP2017505773A/ja active Pending
- 2015-01-26 KR KR1020167023120A patent/KR20160106762A/ko active Application Filing
- 2015-01-26 WO PCT/US2015/012916 patent/WO2015116539A1/en active Application Filing
- 2015-01-26 PT PT191618859T patent/PT3556775T/pt unknown
- 2015-01-26 SI SI201531761T patent/SI3556775T1/sl unknown
- 2015-01-26 EP EP15705137.6A patent/EP3099716A1/en not_active Withdrawn
- 2015-01-26 US US15/108,729 patent/US20160326248A1/en not_active Abandoned
- 2015-01-26 DK DK19161885.9T patent/DK3556775T3/da active
- 2015-01-26 PL PL19161885T patent/PL3556775T3/pl unknown
- 2015-01-26 EP EP19161885.9A patent/EP3556775B1/en active Active
- 2015-01-26 HR HRP20212033TT patent/HRP20212033T1/hr unknown
- 2015-01-26 EP EP21201919.4A patent/EP3988572A1/en active Pending
- 2015-01-26 BR BR112016017174A patent/BR112016017174A2/pt active Search and Examination
- 2015-01-26 HU HUE19161885A patent/HUE057817T2/hu unknown
-
2016
- 2016-07-08 MX MX2022007800A patent/MX2022007800A/es unknown
-
2018
- 2018-02-09 US US15/893,102 patent/US20180244773A1/en not_active Abandoned
-
2019
- 2019-08-22 JP JP2019151663A patent/JP2020015737A/ja active Pending
-
2020
- 2020-09-09 US US17/016,092 patent/US20210122820A1/en not_active Abandoned
-
2022
- 2022-01-18 CY CY20221100044T patent/CY1124977T1/el unknown
- 2022-02-25 JP JP2022027920A patent/JP2022068355A/ja active Pending
-
2023
- 2023-07-28 US US18/227,636 patent/US20240150459A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2017505773A (ja) | 2017-02-23 |
US20210122820A1 (en) | 2021-04-29 |
HUE057817T2 (hu) | 2022-06-28 |
EP3099716A1 (en) | 2016-12-07 |
CY1124977T1 (el) | 2022-11-25 |
US20180244773A1 (en) | 2018-08-30 |
EP3556775B1 (en) | 2021-11-17 |
EA201691361A1 (ru) | 2016-12-30 |
US20240150459A1 (en) | 2024-05-09 |
CA2937503A1 (en) | 2015-08-06 |
PL3556775T3 (pl) | 2022-01-31 |
BR112016017174A2 (pt) | 2017-10-03 |
RS62788B1 (sr) | 2022-02-28 |
JP2022068355A (ja) | 2022-05-09 |
WO2015116539A1 (en) | 2015-08-06 |
US20160326248A1 (en) | 2016-11-10 |
PT3556775T (pt) | 2021-12-31 |
JP2020015737A (ja) | 2020-01-30 |
DK3556775T3 (da) | 2022-01-03 |
CN105992595A (zh) | 2016-10-05 |
KR20220147714A (ko) | 2022-11-03 |
EP3988572A1 (en) | 2022-04-27 |
HRP20212033T1 (hr) | 2022-04-01 |
SI3556775T1 (sl) | 2022-02-28 |
LT3556775T (lt) | 2022-01-25 |
ES2902369T3 (es) | 2022-03-28 |
KR20160106762A (ko) | 2016-09-12 |
MX2022007800A (es) | 2022-07-19 |
EP3556775A1 (en) | 2019-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007800A (es) | Anticuerpos anti-gen de activacion de linfocitos gen-3 (lag-3) para usarse en el tratamiento de neoplasias hematologicas. | |
PH12017501042A1 (en) | Anti-cd38 antibodies for treatment of acute myeloid leukemia | |
MX2018006767A (es) | Composiciones y metodos para oncologia inmunologica. | |
EP3800248A3 (en) | Crispr-cas-related methods, compositions and components for cancer immunotherapy | |
EP4219561A3 (en) | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies | |
CL2016002157A1 (es) | Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda | |
MX2020009919A (es) | Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa. | |
GEP20217331B (en) | Anti-tigit antibodies | |
MX370818B (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
AU2019268074A1 (en) | Methods for treating hepcidin-mediated disorders | |
MX2019008065A (es) | Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida. | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2015012297A (es) | Composiciones que comprenden anticuerpos anti-cd38 y carfilzomib. | |
MX2023006416A (es) | Anticuerpos, usos y metodos. | |
EP3191128A4 (en) | Uses of anti-her3 antibodies for treating cancer | |
PH12017501879A1 (en) | Methods for treating cancer | |
EP3349407A4 (en) | METHOD FOR SUPPRESSING SELF-DISTURBANCES THROUGH A FDR SCHEME DEVICE | |
MX2016005393A (es) | Metodos para tratar vhc. | |
MX2019001979A (es) | Agonista de ppar? para el tratamiento de neoplasias hematicas. | |
IN2013MU01113A (es) | ||
EA201692246A1 (ru) | Способ получения 2,6-диметилбензохинона | |
MX369008B (es) | Un proceso mejorado para la preparación de exametazima. | |
MX2019003311A (es) | Metodos para tratamiento de cancer de ovario. |